Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7265221 | PFIZER | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
US7301023 | PFIZER | Chiral salt resolution |
Dec, 2020
(3 years ago) | |
US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(1 year, 1 month ago) | |
US6956027 | PFIZER | N-terminally chemically modified protein compositions and methods |
Mar, 2023
(1 year, 1 month ago) | |
USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(1 year, 7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7842699 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
US6956041 | PFIZER | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
US7091208 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) |
Xeljanz Xr is owned by Pfizer.
Xeljanz Xr contains Tofacitinib Citrate.
Xeljanz Xr has a total of 11 drug patents out of which 7 drug patents have expired.
Expired drug patents of Xeljanz Xr are:
Xeljanz Xr was authorised for market use on 23 February, 2016.
Xeljanz Xr is available in tablet, extended release;oral dosage forms.
Xeljanz Xr can be used as treatment of adult patients with moderately to severely active ulcerative colitis (uc), a method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98, treatment of rheumatoid arthritis.
Drug patent challenges can be filed against Xeljanz Xr from 06 November, 2016.
The generics of Xeljanz Xr are possible to be released after 14 March, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-879) | Dec 14, 2024 |
New Indication(I-761) | Dec 14, 2020 |
New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 23 February, 2016
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis; A method of treating ulcerative colitis, by administering the formulation of ...
Dosage: TABLET, EXTENDED RELEASE;ORAL